Incidence-based mortality projected to be nearly three times higher in Black versus White women
TUESDAY, July 8, 2025 (HealthDay News) — Uterine cancer incidence and mortality rates are projected to increase significantly through 2050, according to a study published online July 1 in Cancer Epidemiology, Biomarkers & Prevention.
Jason D. Wright, M.D., from the Columbia University College of Physicians and Surgeons in New York City, and colleagues developed a natural history model for uterine cancer to project trends through 2050.
The researchers reported that uterine cancer is projected to increase in incidence and mortality through 2050. Black women will experience a disproportionate rise in incidence compared with White women between 2020 and 2050 (86.9 and 74.2 per 100,000, respectively), as well as a rise in mortality (27.9 and 11.2 per 100,000, respectively). For nonendometrioid tumors, White women will experience only a slight increase, while Black women will experience a substantial increase (10.8 and 36.3 per 100,000, respectively). Hypothetical screening and intervention methods were most effective when introduced at age 55 years with declines in cancer incidence that lasted up to 15 years in White women and up to 16 years in Black women.
“There are likely a number of factors that are associated with the increased burden of uterine cancer in Black women,” Wright said in a statement. “They more commonly have aggressive types of uterine cancer, face delayed diagnosis resulting in later-stage disease at diagnosis, and there are often delays in their treatment.”
Several authors disclosed ties to the pharmaceutical industry.
Abstract/Full Text (subscription or payment may be required)
Cancer-Attributable Costs High for Seniors, Vary With Cancer Phase, Type, Race
Hispanic Patients Face Delays in Frontotemporal Dementia Diagnosis
MS-Related Mortality Rates Highest in Non-Hispanic Blacks
Obesity More Likely for Immigrants With Longer Duration of U.S. Residence
Reinitiating Obesity Meds After Bariatric Surgery Tied to Greater One-Year Weight Loss in Youths
Feelings of Hunger Gradually Return With Semaglutide Use
Obesity Treatment for U.S. Adolescents and Young Adults Shifted Rapidly From 2022 to 2026
Setmelanotide Beneficial in Acquired Hypothalamic Obesity